|
CHERCHEUR
INSERM CR1 Permanent researcher |
CONTACTS
00 33 (0)5 62 74 61 42 |
|
EQUIPE 1 :SIGNAUX PROTÉOLYTIQUES DE L'INTESTIN
TEAM 1 : GUT PROTEASE SIGNALS |
Mini CVActuellement :
|
expertise
|
Recherche/projet research/project
Etude du dialogue entre les tumeurs primaires des cancers colorectaux et leurs métastases hépatiques
Nous voulons identifier les échanges existant entre une tumeur primaire située dans le colon et ses métastases hépatiques et comprendre en quoi ce dialogue peut être déterminant dans la polarisation du microenvironnement des métastases mais aussi dans leur développement et leur réponse aux thérapies. Nous ciblons principalement le microenvironnement immunosuppresseur (lymphocytes T régulateurs et aux macrophages de type 2).
Study of the dialogue between primary tumors of colorectal cancer and liver metastases
We want to identify the exchanges between a primary tumor in the colon and liver metastases and understand how this dialogue can be decisive in the polarization of the microenvironment of metastasis but also in their development and their response to therapy. We target mainly immunosuppressive microenvironment (regulatory T cells and type 2 macrophages )
Nous voulons identifier les échanges existant entre une tumeur primaire située dans le colon et ses métastases hépatiques et comprendre en quoi ce dialogue peut être déterminant dans la polarisation du microenvironnement des métastases mais aussi dans leur développement et leur réponse aux thérapies. Nous ciblons principalement le microenvironnement immunosuppresseur (lymphocytes T régulateurs et aux macrophages de type 2).
Study of the dialogue between primary tumors of colorectal cancer and liver metastases
We want to identify the exchanges between a primary tumor in the colon and liver metastases and understand how this dialogue can be decisive in the polarization of the microenvironment of metastasis but also in their development and their response to therapy. We target mainly immunosuppressive microenvironment (regulatory T cells and type 2 macrophages )
Production scientifique scientific production
Publications des deux dernières années :
1. Franck Gallardo, Iotefa Teiti, Philippe Rochaix, Eloise Demilly, Denis Jullien, Bernard Mariamé and Tilkin-Mariamé AF*. Macrocyclic lactones block melanoma growth,metastases development and potentiate activity of anti-BRAF V600 inhibitors. Clinical Skin Cancer 2016 [Epub ahead of print]
2. Sarrabayrouse G, Teiti I, Filali L, Maisongrosse Véronique, Rochaix Philippe and Tilkin-Mariamé AF*. Atorvastatin-Induced Inhibition of Human Melanoma In Vivo Development. Immunother Open Acc 2016, 2:1.
3. Pich C, Teiti I, Sarrabayrouse G, Gallardo F, Gence R, Tilkin-Mariamé AF*. Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity. PLoS One. 2016 Feb 1;11(2):e0148095.
4. Pich C, Sarrabayrouse G, Teiti I, Mariamé B, Rochaix P, Lamant L, Favre G, MaisongrosseV, Tilkin-Mariamé AF*. Melanoma-expressed CD70 is involved in invasion and metastasis. Br J Cancer. 2016 Jan 12; 114(1):63-70.
5. Gros C.P., Desbois N., Michelin C., Demilly E., Tilkin−Mariamé A.F. , Mariamé B., Gallardo F. Synthesis and Antiviral Activity Evaluation of Nitroporphyrins and Nitrocorroles as Potential Agents against Human Cytomegalovirus Infection. ACS Infectious Diseases, 10.1021/acsinfecdis.5b00020, 2015, 1 (8), 350−356.
6. Teiti I, Florie B, Pich C, Gence R, Lajoie-Mazenc I, Rochaix P, Favre G, Tilkin-Mariamé AF*. In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression. Front Oncol. 2015 Jul 14; 5:156.
7. Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé AF, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, Benoist H, Ségui B. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma. Cancer Res. 2015 Jul 1;75(13):2619-28.
1. Franck Gallardo, Iotefa Teiti, Philippe Rochaix, Eloise Demilly, Denis Jullien, Bernard Mariamé and Tilkin-Mariamé AF*. Macrocyclic lactones block melanoma growth,metastases development and potentiate activity of anti-BRAF V600 inhibitors. Clinical Skin Cancer 2016 [Epub ahead of print]
2. Sarrabayrouse G, Teiti I, Filali L, Maisongrosse Véronique, Rochaix Philippe and Tilkin-Mariamé AF*. Atorvastatin-Induced Inhibition of Human Melanoma In Vivo Development. Immunother Open Acc 2016, 2:1.
3. Pich C, Teiti I, Sarrabayrouse G, Gallardo F, Gence R, Tilkin-Mariamé AF*. Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity. PLoS One. 2016 Feb 1;11(2):e0148095.
4. Pich C, Sarrabayrouse G, Teiti I, Mariamé B, Rochaix P, Lamant L, Favre G, MaisongrosseV, Tilkin-Mariamé AF*. Melanoma-expressed CD70 is involved in invasion and metastasis. Br J Cancer. 2016 Jan 12; 114(1):63-70.
5. Gros C.P., Desbois N., Michelin C., Demilly E., Tilkin−Mariamé A.F. , Mariamé B., Gallardo F. Synthesis and Antiviral Activity Evaluation of Nitroporphyrins and Nitrocorroles as Potential Agents against Human Cytomegalovirus Infection. ACS Infectious Diseases, 10.1021/acsinfecdis.5b00020, 2015, 1 (8), 350−356.
6. Teiti I, Florie B, Pich C, Gence R, Lajoie-Mazenc I, Rochaix P, Favre G, Tilkin-Mariamé AF*. In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression. Front Oncol. 2015 Jul 14; 5:156.
7. Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé AF, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, Benoist H, Ségui B. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma. Cancer Res. 2015 Jul 1;75(13):2619-28.
